Fast, In Vivo Model for Drug-Response Prediction in Patients with B-Cell Precursor Acute Lymphoblastic Leukemia

Only half of patients with relapsed B-cell precursor (BCP) acute lymphoblastic leukemia (ALL) currently survive with standard treatment protocols. Predicting individual patient responses to defined drugs prior to application would help therapy stratification and could improve survival. With the purp...

Descripción completa

Detalles Bibliográficos
Autores principales: Gauert, Anton, Olk, Nadine, Pimentel-Gutiérrez, Helia, Astrahantseff, Kathy, Jensen, Lasse D., Cao, Yihai, Eggert, Angelika, Eckert, Cornelia, Hagemann, Anja I.H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7408814/
https://www.ncbi.nlm.nih.gov/pubmed/32668722
http://dx.doi.org/10.3390/cancers12071883

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7408814/
https://www.ncbi.nlm.nih.gov/pubmed/32668722
http://dx.doi.org/10.3390/cancers12071883

Ejemplares similares